Herpes simplex virus oncolytic vaccine therapy in melanoma.
about
Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesViral oncolysis - can insights from measles be transferred to canine distemper virus?Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapyIntralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.Current and planned multicenter trials for patients with primary or metastatic melanoma.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Triple-negative breast cancer: new perspectives for novel therapies.Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategiesArmed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Talimogene laherparepvec in the treatment of melanoma.Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer.The virus that came in from the cold.Optimizing the Targeting of Mouse Parvovirus 1 to Murine Melanoma Selects for Recombinant Genomes and Novel Mutations in the Viral Capsid Gene.Oncolytic viruses: smart therapeutics for smart cancers.A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
P2860
Q33637231-95B7C5FE-BB58-4A4E-AEF5-65B95DE629E8Q33820717-2E4D3A80-04A1-4344-9F72-B6DC8E8287B3Q36323413-3DDD8BDE-513B-4E5A-99B1-DD54C6CC6178Q37076976-6615E862-1185-452C-927C-7470C8AC2445Q37725792-6437C15E-C910-4CE5-875F-B991798D5419Q37920844-3FCDB098-E6FA-4BCB-B7AE-EDBD6819597BQ38025696-988CDB3B-C3F3-46EF-B08B-618E2E97CAC0Q38119171-82809133-CC1D-41B3-9B43-DC1B03C0C667Q38139255-89914803-93D0-4270-95C8-B4A5FEEBA2D1Q38194135-885C3201-8AA7-49D1-BA33-B153CC21C047Q38656524-8D449587-4D5A-4B7D-985F-75F4402E359BQ38985441-3991D2C7-6877-492C-877D-2AD8FE7C0DA6Q45356848-CEE4B222-78BD-4999-B874-CE31D0141D39Q47547580-CFA9D6A6-CFF0-4FFB-B582-7EE30854F174Q51652949-D155EB31-353A-48B0-8EC9-908D588FAF46Q56348401-14D0146B-6886-4167-984D-CA82453D12DE
P2860
Herpes simplex virus oncolytic vaccine therapy in melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@en
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@nl
type
label
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@en
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@nl
prefLabel
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@en
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@nl
P2093
P2860
P1476
Herpes simplex virus oncolytic vaccine therapy in melanoma.
@en
P2093
Howard L Kaufman
Michael Pan
Shanthi Sivendran
Yvonne Saenger
P2860
P304
P356
10.1517/14712598.2010.495383
P407
P577
2010-07-01T00:00:00Z